Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THCV mouth strips for weight loss in obesity
NCT05574049Phase 1Completed
- Sponsor
- Medical Life Care Planners
- Start
- Jan 2022
- Primary completion
- May 2022
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tetrahydrocannabivarin in obesity and metabolic syndrome (3 arms), sponsored by Medical Life Care Planners. Primary endpoints: Weight Loss at 90 days, Decreased abdominal girth at 90 days and 1 more. Started Jan 2022; status: completed.
02
Drugs
tetrahydrocannabivarin
03
Conditions
obesitymetabolic syndrome
Beyond the preview
Go deeper on NCT05574049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05574049.